Specialty drug usage, traditional drug costs drive small rise in 2019 spending: report
Staff | April 14, 2020 Private drug plans saw a slight uptick in costs in 2019 due to the increased use of specialty drugs and higher price points for traditional medications, according to Express Scripts Canada’s annual drug trends report. The report found private drug plan spending per claimant increased one per cent over 2018’s figures. Plans’ annual spend per claimant on specialty drugs — representing just two per cent of claims — increased by 2.8 per cent and spend on traditional medicines per claimant increased 0.1 per cent. “While the overall private drug trend is up one per cent, prescription drug benefits continue to be threatened by the growing use of very high-cost specialty drugs,” said the report. “Sustainability depends on benefits management solutions that translate into lower costs and improved health outcomes.” Read: Growing use of specialty drugs putting pressure on plan sponsors: report The increase in traditional drug spend reversed a 1.8 per cent decrease in 2018, which was due to a 7.2 per cent increase in spending on diabetes drugs and a 16 per cent increase in diabetes supplies and monitoring technology. However, Ontario’s short-lived OHIP+ program and the pan-Canadian Pharmaceutical Alliance price negotiations helped to keep costs lower, noted the report. Looking forward, Express...